Hospital-acquired bacterial pneumonia (HABP) is one of the most common nosocomial infections. Patients with ventilator-associated bacterial pneumonia (VABP) represent an important subpopulation of HABP, and this infection can occur in patients receiving mechanical ventilation for 48 hours or more. Like HABP, VABP is associated with high rates of antibiotic-resistant pathogens and significant mortality. Although the HABP and VABP markets are highly competitive due to a number of products currently available to hospital-based physicians, including many generics, the commercial opportunity for new agents is high, given the increasing multi-drug resistance associated with the causal pathogens, as well as the persisting high mortality rates among these often critically ill patients.
This report focuses on trends in inpatient treatment of HABP and VABP infections and analyzes the physician prescribing practices for these infections, which are often caused by multi-drug resistant Gram-negative pathogens and methicillin-resistant Staphylococcus aureus (MRSA). Further, this study evaluates the advantages and disadvantages of currently available and emerging therapies for HABP and VABP and identifies opportunities for product positioning and differentiation.